TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00746668

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Module 3: Reading Practice with RSVP
Description: In module 3, we wanted to assess only the higher-level effects of reading practice. Subjects practiced reading using stimuli that did not require reading eye movements. An example is short sentences that were presented one word at a time at a single location on a screen (Rapid Serial Visual Presentation \[RSVP\]). At the end of the sentence, subjects reported whether the sentence made sense or not. We also had our subjects practice reading scrolled text. Although, eye movements and saccades may spontaneously occur under the text presentation conditions of this module, they are not the efficient saccades necessary for reading.
Study: NCT02991781

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Varenicline use for smoking cessation
Description: The protocol will consist 1 mg varenicline use twice daily following a 1-week titration for 3 months.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Varenicline use for smoking cessation
Description: The protocol will consist 1 mg varenicline use twice daily following a 1-week titration for 3 months.
Study: NCT00746668

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Module 3: Reading Practice with RSVP
Description: In module 3, we wanted to assess only the higher-level effects of reading practice. Subjects practiced reading using stimuli that did not require reading eye movements. An example is short sentences that were presented one word at a time at a single location on a screen (Rapid Serial Visual Presentation \[RSVP\]). At the end of the sentence, subjects reported whether the sentence made sense or not. We also had our subjects practice reading scrolled text. Although, eye movements and saccades may spontaneously occur under the text presentation conditions of this module, they are not the efficient saccades necessary for reading.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Module 3: Reading Practice with RSVP
Description: In module 3, we wanted to assess only the higher-level effects of reading practice. Subjects practiced reading using stimuli that did not require reading eye movements. An example is short sentences that were presented one word at a time at a single location on a screen (Rapid Serial Visual Presentation \[RSVP\]). At the end of the sentence, subjects reported whether the sentence made sense or not. We also had our subjects practice reading scrolled text. Although, eye movements and saccades may spontaneously occur under the text presentation conditions of this module, they are not the efficient saccades necessary for reading.
Study: NCT02329379

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Levothyroxine
Study: NCT02991781

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Varenicline use for smoking cessation
Description: The protocol will consist 1 mg varenicline use twice daily following a 1-week titration for 3 months.
Study: NCT02631122

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Supraclavicular vs Retroclavicular Nerve Block
Description: An ultrasound-guided supraclavicular or retroclavicular nerve block with 30 ml of 0.5% ropivicaine will be performed on patients scheduled for lower arm surgery; 25 ml to be delivered to the brachial plexus and 5 ml to the intercostal nerve

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Supraclavicular vs Retroclavicular Nerve Block
Description: An ultrasound-guided supraclavicular or retroclavicular nerve block with 30 ml of 0.5% ropivicaine will be performed on patients scheduled for lower arm surgery; 25 ml to be delivered to the brachial plexus and 5 ml to the intercostal nerve
Study: NCT02170974

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIBR 1048 MS polymorph II

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: BIBR 1048 MS polymorph I
Study: NCT00693238

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Low Risk Proton Radiation

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Intermediate Risk Proton Radiation
Study: NCT02991781

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sham Neurofeedback
Description: Subjects will receive equal sessions of sham neurofeedback, and thus serve as a control group for the analysis and design of the study.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Passive Control
Description: Subjects will not receive any intervention, but they will be measured via a clinical and psychometric evaluation with a time-difference of 3 months. This is equal to the intervention time. Hence, the subjects in this intervention type will serve as a control group for the analysis and design of the study.
Study: NCT04520750

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PTX-022
Description: Safety and Efficacy of PTX-022 in the Treatment of Adults with Pachyonychia Congenita
Study: NCT02991781

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Passive Control
Description: Subjects will not receive any intervention, but they will be measured via a clinical and psychometric evaluation with a time-difference of 3 months. This is equal to the intervention time. Hence, the subjects in this intervention type will serve as a control group for the analysis and design of the study.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Passive Control
Description: Subjects will not receive any intervention, but they will be measured via a clinical and psychometric evaluation with a time-difference of 3 months. This is equal to the intervention time. Hence, the subjects in this intervention type will serve as a control group for the analysis and design of the study.
Study: NCT00174499

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 2 mg nicotine gum
Description: 2 mg nicotine gum

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 4 mg nicotine gum
Description: 4 mg nicotine gum
Study: NCT02733237

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: oxytocin treatment
Description: intranasal administration of oxytocin (40 IU)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: oxytocin treatment
Description: intranasal administration of oxytocin (40 IU)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo treatment
Description: intranasal administration of placebo (40 IU)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo treatment
Description: intranasal administration of placebo (40 IU)
Study: NCT03104205

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Evaluate home-based MOWI
Description: MOWI will be delivered via video-conferencing in the subject's home in a 3x per week, 26-week program from the coordinating center. It will include an individual dietician-led weekly nutrition session; 2x/week physical therapist-led group exercise session; and remote fitness device monitoring. We plan 5 cohorts of 8 subjects (n=40). In-person Research Assistant-led assessments will occur at 0, 8, 16 and 26 weeks. Recruitment, screening, selection criteria, and usability parallel Aim 2 (NCT03104192).
Study: NCT03649737

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise Intervention
Description: Attend supervised and unsupervised exercise sessions

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Survey Administration
Description: Ancillary studies
Study: NCT03296644

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Class II correction using PowerScope2

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Class II correction using Forsus
Study: NCT03649737

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study: NCT01806974

Intervention type: OTHER
Group type: OTHER
Intervention: oral exam and
Description: The study will be conducted with patient presenting a rheumatoid arthritis and for which an anti IL6 biotherapy treatment is planned. Each patient will benefit a record oral exam that will evaluate his periodontal status and on a possible periodontitis associated. Bacterial samples and cytokine will be realized (in defined periodontal pocket or in the most affected periodontal pocket depending of the periodontal status of patients) before the IL6 biotherapy and 6 month after. A periodontal charting will be realized at the same time.

Intervention type: OTHER
Group type: OTHER
Intervention: oral exam and
Description: The study will be conducted with patient presenting a rheumatoid arthritis and for which an anti IL6 biotherapy treatment is planned. Each patient will benefit a record oral exam that will evaluate his periodontal status and on a possible periodontitis associated. Bacterial samples and cytokine will be realized (in defined periodontal pocket or in the most affected periodontal pocket depending of the periodontal status of patients) before the IL6 biotherapy and 6 month after. A periodontal charting will be realized at the same time.
Study: NCT00197756

Intervention type: DIETARY_SUPPLEMENT
Intervention: Vitamin A alone
Description: 30 mg beta-carotene plus 5000 IU preformed vitamin A) taken orally once per during pregnancy and lactation

Intervention type: DIETARY_SUPPLEMENT
Intervention: Vitamin A alone
Description: 30 mg beta-carotene plus 5000 IU preformed vitamin A) taken orally once per during pregnancy and lactation
Study: NCT02660567

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Amr maneuver
Description: sustained traction of the anterior and posterior lips of the cervix by ovum forceps downwards and anteriorly until maximum yield for about 90 seconds
Study: NCT02642120

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Dental device Laboraide
Description: After giving consent, randomization will be carried out using sealed envelopes. After randomization women will be offered to withdraw consent. Women assigned to the study group will receive a sealed Laboraide™ package.~Labor follow up will be documented regularly including outcome. The use of the DSD will not affect the regular management of labor according to the routine standards of the delivery suite. Following delivery, patients will be asked to complete a satisfaction questionnaire.
Study: NCT00827905

Intervention type: DEVICE
Intervention: RSpot Non-Contact Respiratory Rate Spot Check
Description: The Kai Sensors RSpot 100 provides a measurement of respiratory rate at a single point in time. It uses a low-power radar to detect respiratory effort, and analyzes the respiratory effort signal to provide a respiratory rate.
Study: NCT01941849

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vandetanib
Description: 100 mg, 200 mg or 300 mg taken once a day during each 12-weekly cycle

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: 131I-mIBG
Description: Activity will be prescribed to deliver whole body absorbed dose of 0.5 Gy (+/-10%)
Study: NCT02254590

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Irrigation Endoscopic Decompressive Laminotomy
Description: 2 portals 0.5cm were used one for the endoscope and the other for instruments. For every additional level one portal is added. The endoscope and instruments are directly placed over the surface of lamina without any dissection and saline under pump pressure is used to open a potential working space. Unilateral laminotomy/laminectomy is performed according to the severity of stenosis, followed by bilateral decompression beneath the midline structures.
Study: NCT03555318

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Ambulatory visit
Description: All patients will have an ambulatory visit with the cardiologist.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Combined ambulatory visit
Description: Both the geriatrician and cardiologist will evaluate the patient and cardiac treatment will be agreed on between both specialists.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Geriatric intervention
Description: After the geriatric assessment, measures to improve frailty will be started.
Study: NCT03998384

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: retrobulbar injection of autoserum
Description: Retrobulbar block is usually a type of regional anesthetic nerve block used in intraocular surgery. In this technique, local autoserum is injected into the retrobulbar space for the neurotrophic purpose.
Study: NCT00197756

Intervention type: DIETARY_SUPPLEMENT
Intervention: Vitamin A alone
Description: 30 mg beta-carotene plus 5000 IU preformed vitamin A) taken orally once per during pregnancy and lactation

Intervention type: DIETARY_SUPPLEMENT
Intervention: Multivitamins excluding vitamin A
Description: 30 mg thiamine, 20 mg riboflavin, 20 mg B-6, 100 mg niacin, 50 ug vitamin B-12, 500 mg vitamin C, 30 mg vitamin E, 0.8 mg folic acid taken orally once per day during pregnancy and lactation

Intervention type: DIETARY_SUPPLEMENT
Intervention: Multivitamins excluding vitamin A
Description: 30 mg thiamine, 20 mg riboflavin, 20 mg B-6, 100 mg niacin, 50 ug vitamin B-12, 500 mg vitamin C, 30 mg vitamin E, 0.8 mg folic acid taken orally once per day during pregnancy and lactation

Intervention type: DIETARY_SUPPLEMENT
Intervention: multivitamins including vitamin A
Description: 20 mg thiamine, 20 mg riboflavin, 25 mg vitamin B6, 100 mg niacin, 50 ug vitamin B12, 500 mg vitamin C, 30 mg vitamin E, and 0.8 mg folic acid taken once per day orally during pregnancy and lactation
Study: NCT03998384

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: retrobulbar injection of placebo
Description: Retrobulbar block is usually a type of regional anesthetic nerve block used in intraocular surgery. In this technique, normal saline (NS) is injected into the retrobulbar space as a comparison
Study: NCT04463251

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: RPH-104 80 mg
Description: solution for subcutaneous administration 40 mg/mL, 2 mL in the 4-mL transparent glass vial

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: RPH-104 80 mg
Description: solution for subcutaneous administration 40 mg/mL, 2 mL in the 4-mL transparent glass vial

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Normal Saline (0.9% Sodium Chloride solution for Injection), 2 mL in the 4-mL transparent glass vial

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Normal Saline (0.9% Sodium Chloride solution for Injection), 2 mL in the 4-mL transparent glass vial
Study: NCT04490512

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: FluBHPVE6E7
Description: Multiple subcutaneous, intradermal or intramuscular administrations

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: FluBHPVE6E7
Description: Multiple subcutaneous, intradermal or intramuscular administrations
Study: NCT03505684

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: CTP
Description: 1,000 mg of CTP was orally administered per day for 12 weeks.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: placebo (starch)
Description: placebo (starch)
Study: NCT00827216

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: For all patients, a standardised volume of 10 ml of the study drug (will be diluted in 90 ml NaCl 0.9% (total volume, 100 ml). Both, the study drug and the 90 ml NaCl bag will be prepared by the pharmacy. Using sterile syringes, the investigator will withdraw from this solution as many millilitres as necessary to obtain a volume that corresponds to 1 ml per kg bodyweight of the patient (i.e. for a 67 kg patient, 33 ml would be with withdrawn). Thus, the maximum volume that can be administered to a patient will be 100 ml (i.e. for a patient weighing ≥100 kg). Twenty minutes prior to the scheduled induction of anaesthesia, patients will receive their study drug solution as an intravenous infusion during 5 min.
Study: NCT00197756

Intervention type: DIETARY_SUPPLEMENT
Intervention: multivitamins including vitamin A
Description: 20 mg thiamine, 20 mg riboflavin, 25 mg vitamin B6, 100 mg niacin, 50 ug vitamin B12, 500 mg vitamin C, 30 mg vitamin E, and 0.8 mg folic acid taken once per day orally during pregnancy and lactation

Intervention type: OTHER
Intervention: Placebo
Description: Placebo pill taken orally once per day during pregnancy and lactation
Study: NCT00827216

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Erythromycin
Description: For all patients, a standardised volume of 10 ml of the study drug (will be diluted in 90 ml NaCl 0.9% (total volume, 100 ml). Both, the study drug and the 90 ml NaCl bag will be prepared by the pharmacy. Using sterile syringes, the investigator will withdraw from this solution as many millilitres as necessary to obtain a volume that corresponds to 1 ml per kg bodyweight of the patient (i.e. for a 67 kg patient, 33 ml would be with withdrawn). Thus, the maximum volume that can be administered to a patient will be 100 ml (i.e. for a patient weighing ≥100 kg). Twenty minutes prior to the scheduled induction of anaesthesia, patients will receive their study drug solution as an intravenous infusion during 5 min. The regimen corresponds to 3 mg/kg of erythromycin.
Study: NCT00687843

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tegafur-gimeracil-oteracil potassium (TS-1)
Description: 80 mg/m2, PO from day 1 to day 28 of each 42 day cycle. Number of Cycles: 8

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tegafur-gimeracil-oteracil potassium (TS-1)
Description: 80 mg/m2, PO from day 1 to day 28 of each 42 day cycle. Number of Cycles: 8

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Krestin (PSK)
Description: 3 g, PO from day 1 to day 336
Study: NCT01829100

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Group Behavioral Activation Therapy (GBAT)
Description: GBAT consists of 15 weekly, hour-long sessions. The first five group sessions teach four core BA principles: (a) psychoeducation of anxiety and depression, (b) functional analysis and identifying the maintaining role of avoidance, (c) problem solving and approach-oriented decision-making, and (d) graded exposures and behavioral activation. The second five group sessions consist of graded exposures or engagement exercises, where group members take turns practicing skills in role plays and in vivo exposures. Each youth receives two individual meetings (30-45 minutes) after the second and fourth group sessions. The first individual meeting promotes engagement and motivation for the group; the second helps develop the youth's individual avoidance/challenge hierarchy.
Study: NCT00197756

Intervention type: OTHER
Intervention: Placebo
Description: Placebo pill taken orally once per day during pregnancy and lactation
Study: NCT02550756

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CTNX-4975

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CTNX-4975
Study: NCT02537132

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Adaptation and training to Non Invasive Ventilation (NIV)
Description: Each person recruited after a respiratory evaluation (baseline spirometry and supine, maximal inspiratory and expiratory pressures (MIP / MEP) or sniff nasal inspiratory pressure (SNIP), 6 Minute Walking Test (6MWT) -if still ambulatory, arterial blood gas, nocturnal polygraphy) will be adapted to Non Invasive Ventilation (NIV). Moreover, the subject will be brought to the management of bronchial secretions (under the terms set out herein) during not less than five outpatient or house accesses, depending on who is randomly assigned to the experimental group or the control group. These accesses will take place weekly, for a period of two months, considering both the needs and the patient's clinical condition.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Adaptation and training to Non Invasive Ventilation (NIV)
Description: Each person recruited after a respiratory evaluation (baseline spirometry and supine, maximal inspiratory and expiratory pressures (MIP / MEP) or sniff nasal inspiratory pressure (SNIP), 6 Minute Walking Test (6MWT) -if still ambulatory, arterial blood gas, nocturnal polygraphy) will be adapted to Non Invasive Ventilation (NIV). Moreover, the subject will be brought to the management of bronchial secretions (under the terms set out herein) during not less than five outpatient or house accesses, depending on who is randomly assigned to the experimental group or the control group. These accesses will take place weekly, for a period of two months, considering both the needs and the patient's clinical condition.
Study: NCT01722825

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY2157299
Description: Administered orally.
Study: NCT03324386

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Experimental: Individual Orientation
Description: This approach may be individual orientation with by an embracement strategy (relational strategies) may be making 7 nursing visits at 20-day intervals, for 4 month.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Experimental: Individual Orientation
Description: This approach may be individual orientation with by an embracement strategy (relational strategies) may be making 7 nursing visits at 20-day intervals, for 4 month.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Experimental: Individual Orientation
Description: This approach may be individual orientation with by an embracement strategy (relational strategies) may be making 7 nursing visits at 20-day intervals, for 4 month.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Experimental: VLE for Distance Learning
Description: Experimental: This approach may be associated with the use of educational technology (E-Care of Hypertension) in a virtual learning environment(VLE) for distance learning (DL) consultation with the health professional and making 7 nursing visits at 20-day intervals, for 4 months

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Experimental: VLE for Distance Learning
Description: Experimental: This approach may be associated with the use of educational technology (E-Care of Hypertension) in a virtual learning environment(VLE) for distance learning (DL) consultation with the health professional and making 7 nursing visits at 20-day intervals, for 4 months

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Experimental: E-blended Lerarning
Description: This approach may be associated with the use of educational technology (E-Care of Hypertension) in the blended e-learning mode associated with face-to-face with the health professional and making 7 nursing visits at 20-day intervals, for 4 months

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Experimental: E-blended Lerarning
Description: This approach may be associated with the use of educational technology (E-Care of Hypertension) in the blended e-learning mode associated with face-to-face with the health professional and making 7 nursing visits at 20-day intervals, for 4 months

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Conventional Therapy - Control Group
Description: This approach may be individual orientation with conventional therapy may be making 2 nursing visits at baseline and 1 after 120 days,